Novo Nordisk and Anthropic on September 16, 2026 announced a strategic collaboration that puts Anthropic's Claude models — including the new Claude Science research workbench — at the centre of the Danish drug-maker's discovery and development pipeline. The deal follows an internal success story: NovoScribe, an in-house documentation platform built on Claude, has already cut the time to draft a clinical-study report from more than ten weeks to about ten minutes.
Where Claude Fits In R&D
Under the partnership, Novo Nordisk will test Claude Science across specific R&D workflows spanning target identification, molecular design, translational biology and clinical documentation. The companies say the aim is to shore up biological reasoning inside Novo's teams, accelerate AI-driven software development, and let researchers spend more time on judgement calls and less on drafting. Both sides emphasise "robust data governance and human oversight" as guardrails on any patient-facing use.
Executive Framing
Novo Nordisk CEO Mike Doustdar said working with Anthropic will "supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases." Anthropic CEO Dario Amodei pitched the collaboration in the loftier terms that have become his signature: "AI's increasing capability brings with it the potential to compress a century's worth of biological and medical breakthroughs into a decade."
Building On NovoScribe
The 90%+ time reduction NovoScribe already delivers is the concrete data point Novo Nordisk is using to justify pushing Claude further up the value chain. Getting to a clinical-study report in minutes instead of weeks is significant on its own; if the workflow generalises to other regulatory dossiers, it would compress a chunk of pharma bookkeeping that has resisted software for years. It also complements Anthropic's push into vertical AI — the same play we tracked in our recent coverage of Claudeforce inside Salesforce and Anthropic's Bay Area wet-lab expansion.
Why It Matters
The pharma industry has been quicker than most to adopt LLMs for documentation and slower on the science, wary of regulatory exposure and hallucination risk. A named collaboration between a top-five pharma company and a frontier-model lab is one of the strongest signals yet that "AI-first" R&D is moving from experimental cells inside drug companies to enterprise-scale rollouts. It also puts pressure on rival labs — Emulate's $700M raise this week and DeepMind's Isomorphic Labs both operate in the same space — to name comparable pharma partners.
Reporting based on coverage from Unite.AI, BioSpace, PharmExec, BioPharma Dive and joint materials from Novo Nordisk and Anthropic.